Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Vandana Singh

4606 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Top Stories
  • Trading Ideas

What’s Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

By Vandana Singh
May 24, 8:45 AM
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.

AMGN

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Financing
  • General
  • Health Care
  • Movers
  • News
  • Offerings
  • Price Target
  • Top Stories
  • Trading Ideas

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe

By Vandana Singh
May 23, 2:30 PM
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

CYTK

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies

By Vandana Singh
May 23, 2:00 PM
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

AZN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Top Stories

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

By Vandana Singh
May 23, 12:53 PM
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.

AZN

Read More
1 minute read
  • Analyst Ratings
  • General
  • Health Care
  • News
  • Price Target
  • Upgrades

GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities

By Vandana Singh
May 23, 12:38 PM
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contracting initiatives, and manufacturing solutions expansion.

GDRX

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Top Stories

Johnson & Johnson’s Bankruptcy Tactics Are Fraudulent, Plaintiffs Accuse Company Of Defrauding Cancer Victims

By Vandana Singh
May 23, 11:26 AM
Cancer victims have filed a lawsuit against Johnson & Johnson, accusing the company of fraudulently using a shell company's bankruptcy to evade lawsuits. The plaintiffs claim the "Texas two-step" maneuver was designed to protect J&J's assets from litigation.

JNJ

Read More
2 minute read
  • Dividends
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories

Medtronic’s Q4 Earnings: Medical Device Giant Clocks Strong Sales From Neurology Devices, Hikes Dividend

By Vandana Singh
May 23, 11:14 AM
Medtronic reported Q4 2024 sales of $8.59 billion, with 0.5% reported and 5.4% organic revenue growth. Dividend increased to $0.70 per share. FY 2025 EPS guidance is $5.40-$5.50.

MDT

Read More
1 minute read
  • Movers
  • News
  • Top Stories

First Advanced Oral Treatment For Asthma – Sanofi’s Investigational Drug Shows Potential

By Vandana Singh
May 22, 1:59 PM
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

GSK

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • Media
  • News

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M

By Vandana Singh
May 22, 1:25 PM
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous $834 million judgment

BMY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review

By Vandana Singh
May 22, 1:21 PM
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.

NVO

Posts pagination

Previous 1 … 13 14 15 … 461 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service